The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2008Calpain Inhibitors to treat Parkinsons Disease
Objective/Rationale:
Activation of the calcium activated protease, calpain, has been implicated in the initiation of the process of neuronal degeneration associated with PD. Thus, inhibition of... -
Rapid Response Innovation Awards, 2008Measuring Metabolism of Alpha-synuclein in Extracellular Fluids
Objective/Rationale:
Accumulation of the alpha-synuclein protein inside neurons in particular regions of the brain is one of the hallmarks of Parkinson’s disease. Studies suggest that lowering the... -
Rapid Response Innovation Awards, 2008Exploring LRRK2 Substrate(s) for Parkinson Disease by Protein Arrays
Objective/Rationale:
Mutations in the leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of PD. A major gap in our understanding of how LRRK2 causes PD is the lack of knowledge of... -
Clinical Intervention Awards, 2008Simvastatin for the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
Objective/Rationale:
Levodopa-induced dyskinesias are caused by an increased response of dopamine receptors to dopamine in the striatum. Among other intracellular pathways, the MAP kinase signaling... -
Clinical Intervention Awards, 2008Phase II Study of Isradipine as a Disease-modifying Agent in Early Parkinson's Disease
Objective/Rationale:
Isradipine, a drug approved by the FDA for treatment of high blood pressure, has been found to be neuroprotective in pre-clinical models of parkinsonism. The objective of this... -
Therapeutics Development Initiative -- Academic Track, 2008miRNA-based Therapy for Parkinson's Disease
Objective/Rationale:
A central pathological finding associated with PD is the presence of distinctive, abnormal aggregates in brain cells typically lost in PD, termed dopamine neurons. These...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.